HLA-A*11:01 (AA 25-305), (Monomer) protein (His-Avi Tag,KRAS G12C)

Produktnummer ABIN7454281

Dieses Recombinant -Protein wird in HEK-293 Cells produziert.

Kurzübersicht für HLA-A*11:01 (AA 25-305), (Monomer) protein (His-Avi Tag,KRAS G12C) (ABIN7454281)

Target: HLA-A*11:01

Protein-Typ: Recombinant

Spezies: Human

Quelle: HEK-293 Cells

Reinheit: > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC

Produktdetails

Proteineigenschaft: AA 25-305, Monomer

Aufreinigungstag / Konjugat: His-Avi Tag,KRAS G12C

Verwendungszweck: Human HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein

Sequenz: Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M)and VVVGACGVGK peptide

Spezifität: Uni-Prot: AAV53343.1 (HLA-A*11:01), P61769 (B2M), VVVGACGVGK

Produktmerkmale: Recombinant Human HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGACGVGK peptide.

Sterilität: 0.22 μm filtered

Endotoxin-Niveau: Less than 1EU per μg by the LAL method.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Haltbarkeit: 12 months

Antigendetails

Target: HLA-A*11:01

Hintergrund: Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

Molekulargewicht: 50.30 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on Tris-Bis PAGE result.